JP2016509029A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509029A5
JP2016509029A5 JP2015558205A JP2015558205A JP2016509029A5 JP 2016509029 A5 JP2016509029 A5 JP 2016509029A5 JP 2015558205 A JP2015558205 A JP 2015558205A JP 2015558205 A JP2015558205 A JP 2015558205A JP 2016509029 A5 JP2016509029 A5 JP 2016509029A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
morpholinyl
oxo
bis
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509029A (ja
JP6417338B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016971 external-priority patent/WO2014130470A1/en
Publication of JP2016509029A publication Critical patent/JP2016509029A/ja
Publication of JP2016509029A5 publication Critical patent/JP2016509029A5/ja
Application granted granted Critical
Publication of JP6417338B2 publication Critical patent/JP6417338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558205A 2013-02-19 2014-02-18 癌の治療のためのmdm2阻害剤としてのシス−モルホリノン及び他の化合物 Active JP6417338B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766625P 2013-02-19 2013-02-19
US61/766,625 2013-02-19
PCT/US2014/016971 WO2014130470A1 (en) 2013-02-19 2014-02-18 Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016509029A JP2016509029A (ja) 2016-03-24
JP2016509029A5 true JP2016509029A5 (https=) 2017-03-02
JP6417338B2 JP6417338B2 (ja) 2018-11-07

Family

ID=50236309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558205A Active JP6417338B2 (ja) 2013-02-19 2014-02-18 癌の治療のためのmdm2阻害剤としてのシス−モルホリノン及び他の化合物

Country Status (7)

Country Link
US (1) US20160002185A1 (https=)
EP (1) EP2958902B1 (https=)
JP (1) JP6417338B2 (https=)
AU (1) AU2014219075C1 (https=)
CA (1) CA2901696C (https=)
MX (1) MX362896B (https=)
WO (1) WO2014130470A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246148A1 (de) * 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1809282B1 (en) 2004-10-18 2013-01-09 Amgen, Inc Thiadiazole compounds and methods of use
WO2007084391A2 (en) 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
EP2139882B1 (en) 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
DK2137186T3 (en) 2007-03-23 2016-04-18 Amgen Inc Heterocyclic compounds and their uses
CN101809002B (zh) * 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
EP2387570A1 (en) 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド mTORキナーゼ阻害剤としてのインドール/ベンゾイミダゾール化合物
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
CA2765817A1 (en) 2009-06-25 2010-12-29 Amgen Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
SG176986A1 (en) 2009-06-25 2012-02-28 Amgen Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
AU2010265971B2 (en) 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9376425B2 (en) * 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016509029A5 (https=)
JP2009519340A5 (https=)
JP2022542396A5 (https=)
NZ724602A (en) Ror-gamma modulators and uses thereof
JP2022534979A5 (https=)
JP2016503786A5 (https=)
JP2005536475A5 (https=)
JP2006518728A5 (https=)
JP2013532713A5 (https=)
JP2017515844A5 (https=)
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
FI4055021T3 (fi) Heterosyklisiä rip1:tä estäviä yhdisteitä
CA2665476A1 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
CA2785341A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
JP2014532640A5 (https=)
JP2017525757A5 (https=)
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
JP2008504266A5 (https=)
JP2015509975A5 (https=)
JP2017512794A5 (https=)
JP2010536752A5 (https=)
IL278642B1 (en) Purine inhibitors
JP2013530957A5 (https=)
JP2016518344A5 (https=)
RU2014119543A (ru) Новые производные пиразина